Search for: "Generic Pharmaceutical Association" Results 121 - 140 of 3,010
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Jul 2023, 5:58 am by Phil Dixon
Xylazine is a non-opioid sedative or tranquilizer that was first developed in 1962 by the pharmaceutical company Bayer. [read post]
5 Jul 2023, 12:01 pm by admin
The study thus did not find an absence of an association, but rather an inverse association. [read post]
Vital argued the accounts belong to Vital because they are clearly meant to generate revenue for the company, pointing to the fact that the names for each of the accounts include Vital’s brand name, “bangenergy. [read post]
12 Jun 2023, 1:09 pm by admin
Of course, finding statistical significance is just the beginning of assessing the causality of an association. [read post]
2 Jun 2023, 3:16 am by Kluwer IP Reporter
Read the full story here India reverts abandoned trademark applications to original status To comply with the 13 April 2023 decision of the High Court of Delhi, India, in Intellectual Property Attorneys Association (IPAA) & Anr. v. [read post]
1 Jun 2023, 11:53 am by Maike Lorenz (Hoffmann Eitle)
However, a geographical name of a product is no longer eligible for the protection as a geographical indication if it has become generic, i.e. is no longer associated with the geographical origin but with a particular product type or recipe. [read post]
30 May 2023, 11:54 am by Eric Goldman
” Vital argued that “social media accounts are property of a debtor’s estate when the content of the accounts is associated with the debtor’s business and use of the accounts is clearly to generate revenues for the company. [read post]
28 May 2023, 6:58 pm by Stephen Page
 Consequently, same-sex couples face uncertain out-of-pocket costs associated with ART. [read post]
28 May 2023, 6:58 pm by Stephen Page
 Consequently, same-sex couples face uncertain out-of-pocket costs associated with ART. [read post]
15 May 2023, 1:00 pm by Steve Brachmann
The Supreme Court also denied Teva Pharmaceuticals’ petition to review its appeal of the Federal Circuit’s “skinny label” induced infringement ruling over its generic version of carvedilol. [read post]
15 May 2023, 1:00 pm by Steve Brachmann
The Supreme Court also denied Teva Pharmaceuticals’ petition to review its appeal of the Federal Circuit’s “skinny label” induced infringement ruling over its generic version of carvedilol. [read post]
10 May 2023, 3:43 pm by Howard Knopf
Patent practice tends also to be rather polarized overall – especially in pharmaceutical litigation – though this generality may be evolving. [read post]
9 May 2023, 11:55 am by Zamansky LLC
And from that they can bring claims to recover their losses. 01:45 And in securities fraud, they can recover their losses as well. 01:48 Yes, generally securities fraud cases are brought in court. [read post]
8 May 2023, 7:33 am by Kluwer Patent blogger
This seems to be a general problem with the Dutch judiciary. [read post]
6 May 2023, 4:20 pm by Jeralyn
(including through U.S. stings gone awry or the general incompetence or complicity of misguided operations of the ATF or HSI or other agencies?) [read post]
According to a recently published study by Charles River Associates (CRA), prepared for the Fair Standards Alliance, “smartphone-related upstream R&D spend of SEP holders in 2020 amounted, roughly, to only $2 billion. [read post]
2 May 2023, 7:48 am by Rebecca Tushnet
Brookfield Pharmaceuticals, LLC, --- F.Supp.3d ----, 2023 WL 3142311, No. 20-CV-192-JPS (E.D. [read post]